Clovis Oncology is the most expensive short bet on the market, a title once held by Beyond Meat

Clovis Oncology is now the most expensive stock to bet against, according to data from S3 Partners. Beyond Meat used to hold the top spot. Traders now have to pay a 109% borrow fee to short shares of Clovis Oncology. That rate is likely to climb as "there are very few shares left to borrow," Ihor Dusaniwsky of S3 Partners wrote in a Tuesday note. More »